

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability under the Companies Ordinance)

(Stock Code: 00656)

CONTINUING CONNECTED TRANSACTIONS

MUTUAL SUPPLY AGREEMENTS BETWEEN FOSUN PHARMA GROUP AND SINOPHARM GROUP

Reference is made to the Announcement of the Company dated 16 March 2009. Fosun Pharma and Sinopharm entered into the Pharmaceutical Products Supply and Purchase Framework Agreement dated 16 March 2009 for a term of one year commencing from 1 January 2009 and ending on 31 December 2009 in order to govern the mutual supply of certain pharmaceutical products between Fosun Pharma Group and Sinopharm Group. The Pharmaceutical Products Supply and Purchase Framework Agreement will be terminated by the parties on the Commencement Date of the Mutual Supply Agreements (as disclosed below).

According to the management accounts of Fosun Pharma for the seven months ended 31 July 2009, the actual transaction value of the supply of pharmaceutical products by Fosun Pharma Group to Sinopharm Group contemplated under the Pharmaceutical Products Supply and Purchase Framework Agreement was in the amount of RMB47,034,897.91 and the actual transaction value of the supply of pharmaceutical products by Sinopharm Group to Fosun Pharma Group contemplated under the Pharmaceutical Products Supply and Purchase Framework Agreement was in the amount of RMB5,135,276.54.

As disclosed in the Announcement, the annual cap for the supply of pharmaceutical products by Fosun Pharma Group to Sinopharm Group contemplated under the Pharmaceutical Products Supply and Purchase Framework Agreement for the year ending 31 December 2009 was RMB70,000,000 and the annual cap for the supply of pharmaceutical products by Sinopharm Group to Fosun Pharma Group contemplated under the Pharmaceutical Products Supply and Purchase Framework Agreement for the year ending 31 December 2009 was

RMB20,000,000. As at the date of this announcement, the actual transaction values are within the above annual caps.

Fosun Pharma and Sinopharm entered into the Mutual Supply Agreements for a term commencing from the Commencement Date and ending on 31 December 2011, whereby Fosun Pharma Group and Sinopharm Group have agreed to supply pharmaceutical products, healthcare products, medical supplies, chemical reagent and/or laboratory equipment to each other during the term thereof.

Fosun Pharma is a subsidiary of the Company. Fosun Pharma, being a substantial shareholder of Forte, is a connected person of the Company. Sinopharm is an Associate of Fosun Pharma and is therefore a connected person of the Company, and the transactions contemplated under the Mutual Supply Agreements constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

As one or more of the applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) in respect of the annual caps for the Fosun Pharma Supplies for the three years ending 31 December 2009, 31 December 2010 and 31 December 2011, respectively, is more than 0.1% but less than 2.5%, the Fosun Pharma Supplies contemplated under the Mutual Supply Agreements are only subject to the reporting and announcement requirements under Rules 14A.45 to 14A.47 of the Listing Rules, and are exempt from the independent shareholders' approval requirement under Rule 14A.48 of the Listing Rules.

As none of the applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) in respect of the annual caps for the Sinopharm Supplies for the three years ending 31 December 2009, 31 December 2010 and 31 December 2011, respectively, is more than 0.1%, the Sinopharm Supplies contemplated under the Mutual Supply Agreements are exempt from the reporting and announcement requirements under Rules 14A.45 to 14A.47 of the Listing Rules and the independent shareholders' approval requirement under Rule 14A.48 of the Listing Rules.

INTRODUCTION

Reference is made to the Announcement of the Company dated 16 March 2009. Fosun Pharma and Sinopharm entered into the Pharmaceutical Products Supply and Purchase Framework Agreement dated 16 March 2009 for a term of one year commencing from 1 January 2009 and ending on 31 December 2009 in order to govern the mutual supply of certain pharmaceutical products between Fosun Pharma Group and Sinopharm Group. The

Pharmaceutical Products Supply and Purchase Framework Agreement will be terminated by the parties on the Commencement Date of the Mutual Supply Agreements (as disclosed below).

According to the management accounts of Fosun Pharma for the seven months ended 31 July 2009, the actual transaction value of the supply of pharmaceutical products by Fosun Pharma Group to Sinopharm Group contemplated under the Pharmaceutical Products Supply and Purchase Framework Agreement was in the amount of RMB47,034,897.91 and the actual transaction value of the supply of pharmaceutical products by Sinopharm Group to Fosun Pharma Group contemplated under the Pharmaceutical Products Supply and Purchase Framework Agreement was in the amount of RMB5,135,276.54.

As disclosed in the Announcement, the annual cap for the supply of pharmaceutical products by Fosun Pharma Group to Sinopharm Group contemplated under the Pharmaceutical Products Supply and Purchase Framework Agreement for the year ending 31 December 2009 was RMB70,000,000 and the annual cap for the supply of pharmaceutical products by Sinopharm Group to Fosun Pharma Group contemplated under the Pharmaceutical Products Supply and Purchase Framework Agreement for the year ending 31 December 2009 was RMB20,000,000. As at the date of this announcement, the actual transaction values are within the above annual caps.

MUTUAL SUPPLY AGREEMENTS BETWEEN FOSUN PHARMA GROUP AND SINOPHARM GROUP

Fosun Pharma and Sinopharm entered into the Mutual Supply Agreements for a term commencing from the Commencement Date and ending on 31 December 2011, whereby Fosun Pharma Group and Sinopharm Group have agreed to supply pharmaceutical products, healthcare products, medical supplies, chemical reagent and/or laboratory equipment to each other during the term thereof.

Pharmaceutical Products Supply Agreement

Date

4 September 2009

Parties

- (i) Fosun Pharma
- (ii) Sinopharm

Continuing Transaction

Pursuant to the Pharmaceutical Products Supply Agreement, it has been agreed that Fosun Pharma Group shall supply pharmaceutical products, healthcare products and medical supplies to Sinopharm Group during the term thereof.

Term and Termination

The Pharmaceutical Products Supply Agreement is for a term commencing from the Commencement Date and ending on 31 December 2011.

Price Determination

Under the Pharmaceutical Products Supply Agreement, the parties have agreed on the price per unit of the pharmaceutical products, healthcare products and medical supplies, respectively, which were determined in accordance with the following pricing principles:

- (a) state-prescribed price;
- (b) where there is no state-prescribed price, then according to relevant state-recommended price;
- (c) where there is no state-recommended price, then according to relevant market price;
or
- (d) where there is no relevant market price, then according to the contracted price, which shall be determined by reference to the historical figures for preceding years, if any.

Pharmaceutical Products Purchase Agreement

Date

4 September 2009

Parties

- (i) Fosun Pharma
- (ii) Sinopharm

Continuing Transaction

Pursuant to the Pharmaceutical Products Purchase Agreement, it has been agreed that Fosun Pharma Group shall purchase pharmaceutical products, healthcare products and medical supplies from Sinopharm Group during the term thereof.

Term and Termination

The Pharmaceutical Products Purchase Agreement is for a term commencing from the Commencement Date and ending on 31 December 2011.

Price Determination

Under the Pharmaceutical Products Purchase Agreement, the parties have agreed on the price per unit of the pharmaceutical products, healthcare products and medical supplies, respectively, which were determined in accordance with the following pricing principles:

- (a) state-prescribed price;
- (b) where there is no state-prescribed price, then according to relevant state-recommended price;
- (c) where there is no state-recommended price, then according to relevant market price;
or
- (d) where there is no relevant market price, then according to the contracted price, which shall be determined by reference to the historical figures for preceding years, if any.

Chemical Reagent and Laboratory Equipment Purchase Agreement

Date

4 September 2009

Parties

- (i) Fosun Pharma
- (ii) Sinopharm

Continuing Transaction

Pursuant to the Chemical Reagent and Laboratory Equipment Purchase Agreement, it has been agreed that Fosun Pharma Group shall purchase chemical reagent and laboratory equipment from Sinopharm Group during the term thereof.

Term and Termination

The Chemical Reagent and Laboratory Equipment Purchase Agreement is for a term commencing from the Commencement Date and ending on 31 December 2011.

Price Determination

Under the Chemical Reagent and Laboratory Equipment Purchase Agreement, the parties have agreed on the price per unit of the chemical reagent and laboratory equipment, respectively, which were determined in accordance with the following pricing principles:

- (a) state-prescribed price;
- (b) where there is no state-prescribed price, then according to relevant state-recommended price;
- (c) where there is no state-recommended price, then according to relevant market price;
or
- (d) where there is no relevant market price, then according to the contracted price, which shall be determined by reference to the historical figures for preceding years, if any.

Historical Transaction Volume

The actual value of the Transactions for the three years ended 31 December 2006, 2007 and 2008, respectively, were as follows:

Transactions	Year ended 31 December 2006 (RMB) Actual value	Year ended 31 December 2007 (RMB) Actual value	Year ended 31 December 2008 (RMB) Actual value
(1) Supply of Pharmaceutical Products, Healthcare Products and Medical Supplies by Fosun Pharma Group to Sinopharm Group	35,059,326.66	31,794,832.53	47,125,387.03
(2) Supply of Pharmaceutical Products, Healthcare Products, Medical Supplies, Chemical Reagent and Laboratory Equipment by Sinopharm Group to Fosun Pharma Group	49,566,784.09	40,860,430.94	12,957,191.51

The annual caps of the Transactions proposed by the Company for the three years ending 31 December 2009, 31 December 2010 and 31 December 2011, respectively, are as follows:

Annual Caps

Transactions	Year ending 31 December 2009 (RMB) Cap	Year ending 31 December 2010 (RMB) Cap	Year ending 31 December 2011 (RMB) Cap
(1) Supply of Pharmaceutical Products, Healthcare Products and Medical Supplies by Fosun Pharma Group to Sinopharm Group	70,000,000	80,000,000	95,000,000
(2) Supply of Pharmaceutical Products, Healthcare Products, Medical Supplies, Chemical Reagent and Laboratory Equipment by Sinopharm Group to Fosun Pharma Group	20,000,000	25,000,000	30,000,000

The Company has determined the annual caps of the Transactions for the three years ending 31 December 2009, 31 December 2010 and 31 December 2011, respectively, by reference to (i) the historical figures in 2006, 2007 and 2008; (ii) the estimated growth of the demand of pharmaceutical products, healthcare products, medical supplies, chemical reagent and/or laboratory equipment by each of Fosun Pharma Group and Sinopharm Group, respectively; and (iii) the estimated growth of the pharmaceutical industry of the PRC in general.

Implementation Agreements

Fosun Pharma Group will enter into, from time to time and as necessary, separate implementation agreements for each specific transaction contemplated under the Mutual Supply Agreements during the term thereof with Sinopharm Group. Each implementation agreement will set out the specific products, price and other relevant specifications.

As the implementation agreements provide for products as contemplated by the Mutual Supply Agreements, as such, they do not constitute new categories of connected transactions. Any such implementation agreement will be within the ambit of the Mutual Supply Agreements and the annual caps, and if exceeded, the Company will comply with the relevant Listing Rules accordingly.

Listing Rules Implications

Fosun Pharma is a subsidiary of the Company. Fosun Pharma, being a substantial shareholder of Forte, is a connected person of the Company. Sinopharm is an Associate of Fosun Pharma and is therefore a connected person of the Company, and the transactions contemplated under the Mutual Supply Agreements constitute continuing connected transactions of the Company under Chapter 14A of the Listing Rules.

As one or more of the applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) in respect of the annual caps for the Fosun Pharma Supplies for the three years ending 31 December 2009, 31 December 2010 and 31 December 2011, respectively, is more than 0.1% but less than 2.5%, the Fosun Pharma Supplies contemplated under the Mutual Supply Agreements are only subject to the reporting and announcement requirements under Rules 14A.45 to 14A.47 of the Listing Rules, and are exempt from the independent shareholders' approval requirement under Rule 14A.48 of the Listing Rules.

As none of the applicable percentage ratios (as defined under Rule 14A.10 of the Listing Rules) in respect of the annual caps for the Sinopharm Supplies for the three years ending 31

December 2009, 31 December 2010 and 31 December 2011, respectively, is more than 0.1%, the Sinopharm Supplies contemplated under the Mutual Supply Agreements are exempt from the reporting and announcement requirements under Rules 14A.45 to 14A.47 of the Listing Rules and the independent shareholders' approval requirement under Rule 14A.48 of the Listing Rules.

General

Appropriate disclosures of the continuing connected transactions will be made in the annual report and accounts of the Company for the three years ending 31 December 2009, 31 December 2010 and 31 December 2011, respectively.

The Directors (including the independent non-executive Directors) are of the view that the terms of the continuing connected transactions contemplated under the Mutual Supply Agreements (i) have been negotiated on an arm's length basis; (ii) have been and will be conducted on normal commercial terms, or on terms no less favourable than those available to and from independent third parties under prevailing local market conditions; (iii) are entered into in the ordinary and usual course of business of the Group; (iv) are fair and reasonable and in the interests of the Shareholders as a whole; and (v) that the annual caps for the three years ending 31 December 2009, 31 December 2010 and 31 December 2011, respectively, are fair and reasonable.

To the best of the Directors' knowledge, information and belief, having made all reasonable enquiry, there is no other continuing transaction entered into between any member of the Group and Sinopharm Group and its ultimate beneficial owner(s) or otherwise related, which would be, together with the continuing connected transactions under the Mutual Supply Agreements, aggregated under Rules 14A.27 of the Listing Rules.

Reasons for entering into the Continuing Connected Transactions

Each of Fosun Pharma Group and Sinopharm Group is principally engaged in the sales and distribution of pharmaceutical and medical products. Each of them supplies pharmaceutical and medical products to the other, being one of its customers, in its ordinary and usual course of business and on normal commercial terms.

GENERAL INFORMATION OF THE GROUP

The principal activities of the Group are: (i) pharmaceuticals; (ii) property development; (iii) steel; (iv) mining; and (v) retail, services and strategic investments.

GENERAL INFORMATION OF THE PARTIES TO THE CONTINUING CONNECTED TRANSACTIONS

Fosun Pharma

Fosun Pharma is a joint stock company incorporated under the laws of the PRC with limited liability and is a subsidiary of the Company. It is principally engaged in the manufacturing, research and development, wholesaling and retailing of pharmaceutical products.

Sinopharm

Sinopharm is a joint stock company incorporated under the laws of the PRC with limited liability. It is principally engaged in the distribution, retailing and logistics of pharmaceutical products.

DEFINITIONS

In this announcement, unless the context otherwise requires, the following expressions have the following meanings:

"Announcement"	the announcement of the Company dated 16 March 2009
"Associate"	has the same meaning ascribed thereto under the Listing Rules
"Chemical Reagent and Laboratory Equipment Purchase Agreement"	a chemical reagent and laboratory equipment purchase agreement dated 4 September 2009 and entered into between Fosun Pharma and Sinopharm in relation to the purchase of chemical reagent and laboratory equipment by Fosun Pharma Group from Sinopharm Group
"Commencement Date"	the date of approval by the shareholders in general meeting of Fosun Pharma in respect of the Mutual Supply Agreements

“Company”	Fosun International Limited (復星國際有限公司), a company incorporated under the laws of Hong Kong and whose shares are listed and traded on the main board of the Stock Exchange
“Director(s)”	the director(s) of the Company
“Forte”	Shanghai Forte Land Co., Ltd. (復地(集團)股份有限公司), a sino-foreign joint stock company incorporated under the laws of the PRC with limited liability and a subsidiary of the Company, the H shares of which are listed and traded on the main board of the Stock Exchange
“Fosun Pharma”	Shanghai Fosun Pharmaceuticals (Group) Company Limited (上海復星醫藥(集團)股份有限公司), a joint stock company incorporated under the laws of the PRC with limited liability and whose A shares are listed and traded on the Shanghai Stock Exchange
“Fosun Pharma Group”	Fosun Pharma and its subsidiaries
"Fosun Pharma Supplies"	the supply of pharmaceutical products, healthcare products and medical supplies by Fosun Pharma Group to Sinopharm Group
“Group”	the Company and its subsidiaries
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange
“Mutual Supply Agreements”	collectively, the Pharmaceutical Products Supply Agreement, the Pharmaceutical Products Purchase Agreement and the Chemical Reagent and Laboratory Equipment Purchase Agreement
“Pharmaceutical Products Purchase Agreement”	a pharmaceutical products purchase agreement dated 4 September 2009 and entered into between Fosun Pharma and Sinopharm in relation to the purchase of pharmaceutical products, healthcare products and medical supplies by Fosun Pharma Group from Sinopharm Group

“Pharmaceutical Products Supply Agreement”	a pharmaceutical products supply agreement dated 4 September 2009 and entered into between Fosun Pharma and Sinopharm in relation to the supply of pharmaceutical products, healthcare products and medical supplies by Fosun Pharma Group to Sinopharm Group
"Pharmaceutical Products Supply and Purchase Framework Agreement"	a pharmaceutical products supply and purchase framework agreement dated 16 March 2009 and entered into between Fosun Pharma and Sinopharm in relation to the mutual supply of pharmaceutical products between Fosun Pharma Group and Sinopharm Group as disclosed in the Announcement
“PRC”	the People’s Republic of China
“RMB”	Renminbi yuan, the lawful currency of the PRC
“Shareholders”	the shareholders of the Company
“Sinopharm”	Sinopharm Group Co., Ltd. (國藥控股股份有限公司), a joint stock company incorporated under the laws of the PRC with limited liability
“Sinopharm Group”	Sinopharm and its subsidiaries
"Sinopharm Supplies"	the supply of pharmaceutical products, healthcare products, medical supplies, chemical reagent and laboratory equipment by Sinopharm Group to Fosun Pharma Group
“Stock Exchange”	The Stock Exchange of Hong Kong Limited
“Transactions”	the transactions contemplated under the Mutual Supply Agreements

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

Shanghai, the PRC, 4 September 2009

As at the date of this announcement, the executive directors of the Company are Guo Guangchang, Mr. Liang Xinjun, Mr. Wang Qunbin, Mr. Fan Wei, Mr. Ding Guoqi, Mr. Qin Xuetao and Mr. Wu Ping; the non-executive director is Mr. Liu Benren; and the independent non-executive directors are Dr. Chen Kaixian, Mr. Zhang Shengman and Mr. Andrew Y. Yan.